Palisade Bio presented data from its lead candidate, PALI‑2108, at the 21st Congress of the European Crohn’s and Colitis Organization (ECCO) in Stockholm, Sweden. The poster, titled “Oral Locally Bioactivated PDE4 Inhibitor Prodrug PALI‑2108 Demonstrates Rapid Clinical, Histologic, and Biomarker Improvement in Ulcerative Colitis: Phase 1b Translational Findings,” reported that all five moderate‑to‑severe ulcerative colitis patients treated for seven days achieved a clinical response, with a subset reaching remission.
The translational data showed a pronounced reduction in colonic expression of key inflammatory pathways—including TNF‑α, JAK‑STAT, NF‑κB, MAPK, and TGF‑β—as well as fibrosis‑associated signatures. Peripheral immune profiles remained largely unchanged, underscoring the drug’s gut‑restricted activity. The rapid clinical response, coupled with biomarker engagement, suggests that the locally activated PDE4 inhibition is effectively dampening inflammation in the target tissue.
PALI‑2108’s mechanism relies on colonic β‑glucuronidase–mediated bioactivation, which delivers high local drug exposure while limiting systemic exposure. Safety data from the 89‑subject Phase 1 study were favorable, with no serious adverse events or treatment‑emergent laboratory or ECG abnormalities reported, reinforcing the safety profile of the gut‑restricted approach.
These findings de‑risk the program and support Palisade’s plan to advance PALI‑2108 into a Phase 2 ulcerative colitis study and a Phase 1b fibrostenotic Crohn’s disease trial. The data position the company as a potential first‑in‑class anti‑fibrotic therapy in a disease area where no approved treatments exist, strengthening its competitive stance in the IBD market.
Management highlighted the rapid clinical response and broad biomarker engagement, reinforcing the program’s de‑risking trajectory and the company’s confidence in progressing to later‑stage development.
Palaisade has attracted significant investor interest, with the stock delivering strong performance over the past year. The translational data are expected to support future funding and accelerate regulatory review and market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.